CEVA awarded Good Distribution Practice (GDP) Award
16 June 2010 - 16:53 CET
IEA Life Sciences Ireland division recognizes CEVA for delivering highest standards to the pharmaceutical and medical devices industry
Dublin, Ireland, 16 June 2010 - CEVA Logistics, one of the world's leading supply chain companies, has been presented with Full Passport Status for Good Distribution Practice (GDP) for providing best-in-class supply chain services to the pharmaceutical, medical device and diagnostics manufacturing sectors by the IEA (Irish Exporters Association) Life Sciences Ireland division.
John Whelan, CEO of the IEA stated: ‘'Ireland is a global centre of excellence in the Life Sciences industry with 18 of the top 20 global brands being produced here. To retain this pre-eminent position in this very competitive and regulated industry we need exceptional logistics supply partners. We are delighted that CEVA has put in the investment to reach the GDP Passport standard and ensure the high level of supply chain support will continue to be made available to the pharmaceutical and medical devices industry to reach their global markets efficiently out of Ireland.‘'
Leigh Pomlett, CEVA's Executive Vice President in UK & Ireland said: "CEVA is committed to operational excellence and our company culture is well aligned to the Life Sciences ethos which focuses on driving export excellence. We are delighted that the IEA Life Sciences has recognized our professionalism in the healthcare sector by presenting CEVA in Ireland with the GDP award."
In order to receive the GDP award, CEVA had to demonstrate its expertise and capabilities within the sector. The process involved an inspection by the IEA of CEVA's premises, transport and vehicles, procedures, records and training which were all assessed against stringent criteria.
Gary O'Connor, CEVA's Country Manager in Ireland, attended the presentation and accepted the award on behalf of CEVA and said: ‘‘CEVA is delighted to receive this prestigious award from the IEA Life Sciences division. CEVA recognizes that cost effective, innovative and compliant solutions are critical to companies operating in the life sciences sector and that the practices that form the basis of the GDP Passport will help to ensure that the logistics sector is well equipped to support Life Sciences in Ireland into the future."
The GDP Passport Code was drawn up by the Life Sciences industry and the IEA in consultation with the Irish Medical Board (IMB) to meet the requirements as set out in the IMB's Guidelines and the requirements of EU Guidelines. The GDP Passport Code aims to bring Ireland to the highest standard required by the highly regulated pharmaceutical and medical devices global industry.
For more information contact:
Lindsey Randle
Communications Officer, CEVA
+44 (0)1530 568709
Lindsey.Randle@cevalogistics.com
Notes to Editors:
The IEA's Life Sciences division in Ireland focuses on a number of critical business areas including good distribution practice; logistical efficiency; material quality control; regulatory response; good manufacturing practice and lobbying. It supports companies in their International trade and supply chain activities and preserves the sector's status as Ireland's fastest growing export grouping.
CEVA operates at three strategic locations in Ireland: Dublin (head office), Cork and Shannon. It employs approximately 80 personnel and specializes in supporting healthcare, consumer and retail and technology market sectors. In addition to the GDP Passport CEVA in Ireland is also accredited with International Organization for Standardization (ISO), TAPA A approved, Authorized Economic Operator (AEO) certification.
Life Sciences Ireland focuses on a number of critical business areas:
- Good distribution practice - benchmarking the standard for the industry and promoting its use by all service providers nationally and internationally.
- Logistical efficiency - promoting and providing access to the latest cost reduction and supply chain efficiency improvement techniques and opportunities.
- Material Quality Control - assisting life sciences companies and those serving the industry to keep up to speed in the latest material handling and environmental control methods and standards.
- Regulatory response - providing training and support to enhance the sector's ‘rapid response' capability to changing regulations and standards.
- Good manufacturing practice - supporting companies achieve and maintain their Goods Manufacturing Practice standards in line with IMB and international regulatory body requirements.
- Lobbying - ensuring that companies within the sector in Ireland have the opportunity to have their views represented at World Health Authority, EU and national government to ensure any new or proposed changes to legislation are efficiently processed.
CEVA - Making business flow
CEVA Logistics provides world class supply chain solutions for large and medium-size national and multinational companies across the globe. As an industry leader, CEVA offers customers complete supply chain design and implementation in contract logistics and freight management, alone or in combination. CEVA's integrated global network has facilities in over 170 countries and more than 46,000 employees; all dedicated to delivering consistently excellent operations and supply chain solutions. For the year ending 31 December 2009, the Group reported revenues of €5.5 billion. For more information, please visit www.cevalogistics.com.
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT of 1995:
The statements included in this news release, and other statements that are not historical facts, may contain forward-looking statements. In addition to the assumptions specifically mentioned in the above paragraphs, there are a number of other factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements. These factors include, but are not limited to, the process of combining EGL and CEVA, the actual effects of recent and future regulatory changes and technological developments, globalization, levels of spending in major economies, the economic downturn in Asia, Europe and the US, including the economic downturn in the automotive sector, levels of marketing and promotional expenditure, actions of competitors and joint venture partners, employee costs, future exchange and interest rates, changes in tax rates, unexpected costs of future business combinations or dispositions and other factors detailed in risk factors and elsewhere in CEVA most recent Annual Reports. Further information concerning the Company and its business, including factors that potentially could materially affect the Company's financial results, is contained in the Company's annual and quarterly reports, available on the Company's website. Should one or more of these risks or uncertainties materialize or the consequences of such a development worsen, or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. CEVA disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.
